PCI Biotech AS   Report issue

For profit Phase 1 Phase 2
Founded: Lysaker Norway (2000)

Organization Overview

First Clinical Trial
2009
NCT00993512
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

PCI Biotech | PCI Biotech AS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Head and Neck Neoplasms (Phase 1)

Neoplasms (Phase 1)

Skin Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 7